Advance Research Base

March 30, 2020

By brianpowell

Latest figures show strong research expenditures for state universities 

UArizona ranks No. 19 among U.S. public research institutions, with more than $734 million in total research activity, according to the latest National Science Foundation data. With $640 million in research activity, ASU is sixth among universities without a medical school and No. 26 overall among public universities, while NAU ranked No. 139 among public universities, with $58 million. 

Phoenix Biomedical Campus adds Wexford research facility, new wet lab and research space 

Construction on the Wexford Science and Technology building, to be anchored by ASU, is completed, and the CEI LabForce incubator and ASU begin moving in. Meanwhile, a $20 million project begins building out 48,000 square feet of lab and research space for the University of Arizona College of Medicine-Phoenix within the Biomedical Sciences Partnership Building. 

C-Path awarded federal contract to improve neuroscience disease trials 

Critical Path Institute, celebrating its 15th year, is awarded an FDA contract to improve the efficiency of trial design for Alzheimer’s disease, Parkinson’s disease, and Duchenne muscular dystrophy. C-Path also launches a consortium to accelerate medical-product development in sickle cell disease and a data-sharing collaboration to accelerate drug development for Type 1 diabetes. 

UArizona awarded grants to fight skin cancer and Alzheimer’s, increase screenings for Native Americans 

The University of Arizona Cancer Center is awarded nearly $10 million through two grants to prevent and decrease the risk of cell carcinoma and to continue collaboration with Native American communities to remove barriers for colorectal cancer screenings. Other grants will further research on therapies to address progression of Alzheimer’s disease, investigate how cells respond to stress, and detect liver tumors. 

Mayo Clinic, TGen researchers target most lethal pancreatic cancer 

A study led by Mayo Clinic and TGen identifies drugs already in use for different cancers and non-cancer conditions that can be used to target the most aggressive and lethal form of pancreatic cancer.